Please note that
since the last submission three years ago, the F DA has ammended
its regulation regarding labeling requirements fo r aluminum
content in LVPs, SVPs and PBPs used in TPN. The final rule was
effective on Jul 26, 2004, and since then, FDA expects to receive
significantly fewer submissions per year, which has be en reflected
in the significant decrease in respondents and burde n hours. If
additional changes are made resulting in a change in burden hours,
the FDA can submit the changes using an 83-C.
Inventory as of this Action
Requested
Previously Approved
07/31/2009
07/31/2009
07/31/2006
10
0
265
140
0
3,710
0
0
0
FDA regulations specify labeling
requirements for the aluminum content in LVPs and PBP's used in
TPN. An upper limit of aluminum is permitted in LVPs and applicants
must submit to FDA validated assay methods for determining aluminum
content in parenteral drug products.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.